Recursion Q2 Loss Narrows and Cash Burn Slows, but Material Weaknesses Persist
RXRX is trading near its 52-week low of $2.77 (7.2% above the low).
Summary
Recursion Pharmaceuticals reported a narrower Q2 2026 net loss of $131 million, down from $172 million a year ago, as cost cuts took hold. Cash reserves fell to $546 million, but the company says it has enough to operate for at least 12 months. Material weaknesses in financial controls remain unresolved.
Key Events · Earnings and Guidance · RXRX
-
Net Loss Narrows Significantly
Driven by a 31% reduction in operating expenses, the Q2 2026 net loss came in at $131.0 million ($0.25/share) versus $171.9 million ($0.41/share) in Q2 2025. For the first half of 2026, the net loss was $248.5 million, down 34% from $374.4 million in H1 2025.
-
Cash Burn Slows but Reserves Decline
Cash and cash equivalents fell to $545.7 million at June 30, 2026, from $743.3 million at year-end 2025. Operating cash burn improved to $187.0 million in H1 2026 from $208.4 million in H1 2025. The company states it has sufficient cash for at least 12 months.
-
Material Weaknesses in Internal Controls Remain
As of June 30, 2026, disclosure controls and procedures were ineffective due to unremediated material weaknesses from the Exscientia acquisition. Remediation efforts are ongoing but not yet complete.
-
Genentech Exercises First Neuroscience Target Option
Validating Recursion's AI-driven target identification platform, Genentech advanced a novel, previously unexplored neuroscience target into a small molecule early discovery program. To date, Recursion has received $216 million in upfront and milestone payments from the Roche/Genentech collaboration.
Analysis · RXRX · Life Sciences
Recursion's Q2 2026 results show a sharply reduced net loss and lower operating expenses, extending its cash runway. However, the company still carries unremediated material weaknesses in internal controls from the Exscientia acquisition, and its cash balance has declined significantly. The pipeline is advancing with a new Genentech neuroscience target entering discovery and key clinical readouts expected in the second half of 2026. The $300 million ATM program remains untapped, providing a financing backstop but also potential dilution overhang.
At the time of this filing, RXRX was trading at $2.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.77 to $7.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.